Description

DM4-SMe is a metabolite of antibody-maytansin conjugates (AMCs) and a tubulin inhibitor, and also a cytotoxic moiety of antibody-drug conjugates (ADCs), which can be linked to antibody through disulfide bond or stable thioether bond. DM4-SMe inhibits KB cells with an IC50 of 0.026 nM[1][2].–20°C, 3 years (Powder)-Applications-Cancer-programmed cell death-Formula-C39H56ClN3O10S2-Citation–References-[1]Widdison W, et al. Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. Mol Pharm. 2015 Jun 1;12(6):1762-73.|[2]Chen H, et al. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2017 Aug 1;22(8).-CASNumber-796073-68-2-MolecularWeight-826.46-Compound Purity-98.0-SMILES-C[C@]12[C@H]([C@@H]([C@](O3)([H])C[C@]([C@](/C=C/C=C(C)/CC4=CC(N(C)C(C[C@]2([H])OC([C@H](C)N(C)C(CCC(C)(C)SSC)=O)=O)=O)=C(C(OC)=C4)Cl)([H])OC)(NC3=O)O)C)O1-Research_Area-Cancer-Solubility-DMSO : 100 mg/mL (ultrasonic)-Target-ADC Cytotoxin;Microtubule/Tubulin-Isoform-Maytansinoids-Pathway-Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton-MCE Product type-ADC Related